Cargando…
Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19
Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data regarding their impact in fully vaccinated vulnerable subjects with mild-to-moderate COVID-19 are still limited, particularly in the...
Autores principales: | Bruno, Giuseppe, Giotta, Massimo, Perelli, Serena, De Vita, Giuseppina, Bartolomeo, Nicola, Buccoliero, Giovanni Battista |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695104/ https://www.ncbi.nlm.nih.gov/pubmed/36423123 http://dx.doi.org/10.3390/v14112514 |
Ejemplares similares
-
Prevalence and Risk Factors for Poor Sleep Quality in People Living with HIV: Preliminary Observations from an HIV Outpatient Clinic
por: Bruno, Giuseppe, et al.
Publicado: (2023) -
Short-term outcomes in individuals aged 75 or older with severe coronavirus disease (COVID-19): First observations from an infectious diseases unit in Southern Italy
por: Bruno, Giuseppe, et al.
Publicado: (2020) -
Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review
por: Bruno, Giuseppe, et al.
Publicado: (2023) -
Fighting Epilepsy with Nanomedicines—Is This the Right Weapon?
por: Matias, Mariana, et al.
Publicado: (2023) -
Cyclosporine: an old weapon in the fight against coronaviruses
por: Molyvdas, Adam, et al.
Publicado: (2020)